awmsg logo



bivalirudin (Angiox®)


Reference No. 62

Publication date:
04/08/2009


Appraisal information

bivalirudin (Angiox®) 250 mg powder for concentrate for solution for injection/infusion


Company: The Medicines Company
BNF category: Cardiovascular system
NMG meeting date: 20/05/2009
AWMSG meeting date: 24/06/2009
   
   
Submission Type: Full Submission
Status: Recommended with restrictions
Advice No: 1009
Ministerial ratification: 22/07/2009

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Bivalirudin (Angiox®) (administered with aspirin and clopidogrel) is recommended as an option within NHS Wales for the treatment of adult patients with acute coronary syndromes (unstable angina/non-ST segment elevation myocardial infarction [UA/NSTEMI]) planned for urgent or early intervention. AWMSG is of the opinion that bivalirudin (Angiox®) is not suitable for shared care within NHS Wales. Bivalirudin (Angiox®) should only be considered as an option where both a glycoprotein IIb/IIIa inhibitor (GPI) plus heparin would be used as an alternative. Bivalirudin (Angiox®) should not be used as an alternative where heparin would be used alone. AWMSG is of the view that the main place in therapy for bivalirudin (Angiox®) is where there is a high risk of bleeding.
Final Appraisal Recommendation (FAR)
Download